Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
19 hedge funds and large institutions have $5.5M invested in Checkpoint Therapeutics in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
27% more funds holding
Funds holding: 15 → 19 (+4)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.15% less ownership
Funds ownership: 1.27% → 1.12% (-0.15%)
52% less capital invested
Capital invested by funds: $11.4M → $5.5M (-$5.91M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fenimore Asset Management
Cobleskill,
New York
|
+$238K |
| 2 |
BII
Bainco International Investors
Boston,
Massachusetts
|
+$126K |
| 3 |
Renaissance Technologies
New York
|
+$84.5K |
| 4 |
Bank of New York Mellon
New York
|
+$47.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$982K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$26.6K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
-$15.2K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7K |
| 5 |
BlackRock
New York
|
-$929 |
CKPT Hedge Fund Activity: Q4 2018 in Review
19 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q4 2018, worth a combined $5.5M — down 52% from $11.4M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CKPT positions and 1 closed out — a net gain of 4 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Fenimore Asset Management, opening a new position worth an estimated $238K. The largest seller was Vanguard Group, cutting an estimated $982K.
- 19 institutional investors held Checkpoint Therapeutics (CKPT) as of Q4 2018, up from 15 in Q3 2018.
- Funds reported $5.5M of Checkpoint Therapeutics stock for Q4 2018, down 52% quarter-over-quarter.
- 5 funds opened new Checkpoint Therapeutics positions in Q4 2018 and 1 closed out, a net change of +4 holders.
- The largest Checkpoint Therapeutics buyer in Q4 2018 was Fenimore Asset Management, an estimated $238K added.
- The largest Checkpoint Therapeutics seller in Q4 2018 was Vanguard Group, an estimated $982K sold.
Based on aggregated 13F filings for Q4 2018.